{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:14:44Z","timestamp":1790266484226,"version":"4.1.0"},"reference-count":78,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","award":["II-ON"],"award-info":[{"award-number":["II-ON"]}],"id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["NK12015-7710"],"award-info":[{"award-number":["NK12015-7710"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["10653"],"award-info":[{"award-number":["10653"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["NK12015-7542"],"award-info":[{"award-number":["NK12015-7542"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.xcrm.2025.102512","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T15:36:26Z","timestamp":1765899386000},"page":"102512","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["CfDNA-based copy-number dynamics during anti-PD1 treatment in metastatic triple negative breast cancer"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-7519-0853","authenticated-orcid":false,"given":"Aaron Y.","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga I.","family":"Isaeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teoman","family":"Deger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veerle C.M.","family":"Geurts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daan C.L.","family":"Vessies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonie","family":"Voorwerk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten","family":"Slagter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kat S.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"van der Leest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.M.","family":"Martens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daan","family":"van den Broek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lodewyk F.A.","family":"Wessels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9043-9815","authenticated-orcid":false,"given":"Marleen","family":"Kok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2025.102512_bib1","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","article-title":"Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence","volume":"13","author":"Dent","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102512_bib2","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1056\/NEJMra1001389","article-title":"Triple-Negative Breast Cancer","volume":"363","author":"Foulkes","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2025.102512_bib3","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1002\/cncr.23930","article-title":"Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer","volume":"113","author":"Lin","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.xcrm.2025.102512_bib4","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13058-019-1210-4","article-title":"Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review","volume":"21","author":"Li","year":"2019","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102512_bib5","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ejca.2018.03.015","article-title":"Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort","volume":"96","author":"Gobbini","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.xcrm.2025.102512_bib6","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2025.102512_bib7","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2025.102512_bib8","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.annonc.2021.05.355","article-title":"First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis","volume":"32","author":"Emens","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2025.102512_bib9","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S1470-2045(19)30689-8","article-title":"Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"21","author":"Schmid","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2025.102512_bib10","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s10549-021-06287-4","article-title":"Seeing the forest and the tree: TILs and PD-L1 as immune biomarkers","volume":"189","author":"Savas","year":"2021","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.xcrm.2025.102512_bib11","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1093\/jnci\/djab004","article-title":"Atezolizumab and nab -Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study","volume":"113","author":"Emens","year":"2021","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.xcrm.2025.102512_bib12","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/path.5406","article-title":"The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice","volume":"250","author":"Paula","year":"2020","journal-title":"J. Pathol."},{"key":"10.1016\/j.xcrm.2025.102512_bib13","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/s41467-017-00965-y","article-title":"Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors","volume":"8","author":"Adalsteinsson","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102512_bib14","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1158\/1078-0432.CCR-15-0943","article-title":"ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients","volume":"22","author":"Chu","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102512_bib15","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.annonc.2022.11.005","article-title":"Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer","volume":"34","author":"Turner","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2025.102512_bib16","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.annonc.2020.11.007","article-title":"Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival","volume":"32","author":"Magbanua","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2025.102512_bib17","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/s43018-020-0096-5","article-title":"Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab","volume":"1","author":"Bratman","year":"2020","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.xcrm.2025.102512_bib18","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1002\/1878-0261.13094","article-title":"Clinical potential of circulating free DNA and circulating tumour cells in patients with metastatic non-small-cell lung cancer treated with pembrolizumab","volume":"15","author":"Mondelo-Mac\u00eda","year":"2021","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.xcrm.2025.102512_bib19","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1093\/annonc\/mdy024","article-title":"Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis","volume":"29","author":"Bareche","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2025.102512_bib20","first-page":"543","article-title":"Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer","volume":"36","author":"Stover","year":"2018","journal-title":"J. Clin. Orthod."},{"key":"10.1016\/j.xcrm.2025.102512_bib21","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/s41467-023-36801-9","article-title":"Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer","volume":"14","author":"Prat","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102512_bib22","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaf8399","article-title":"Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy","volume":"355","author":"Davoli","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2025.102512_bib23","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/jnci\/djz208","article-title":"Unraveling Triple-Negative Breast Cancer Tumor Microenvironment Heterogeneity: Towards an Optimized Treatment Approach","volume":"112","author":"Bareche","year":"2020","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.xcrm.2025.102512_bib24","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/jnci\/djad080","article-title":"Copy number aberrations in circulating tumor DNA enables prognosis prediction and molecular characterization of breast cancer","volume":"115","author":"Kim","year":"2023","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.xcrm.2025.102512_bib25","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/1878-0261.13409","article-title":"Dynamic changes in circulating tumor DNA assessed by shallow whole-genome sequencing associate with clinical efficacy of checkpoint inhibitors in NSCLC","volume":"17","author":"Carbonell","year":"2023","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.xcrm.2025.102512_bib26","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1158\/1535-7163.MCT-18-0535","article-title":"Genome-Wide Sequencing of Cell-Free DNA Identifies Copy-Number Alterations That Can Be Used for Monitoring Response to Immunotherapy in Cancer Patients","volume":"18","author":"Jensen","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.xcrm.2025.102512_bib27","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41591-019-0432-4","article-title":"Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial","volume":"25","author":"Voorwerk","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2025.102512_bib28","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1002\/1878-0261.13174","article-title":"A pipeline for copy number profiling of single circulating tumour cells to assess intrapatient tumour heterogeneity","volume":"16","author":"Deger","year":"2022","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.xcrm.2025.102512_bib76","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1093\/annonc\/mdu479","article-title":"Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data","volume":"26","author":"Favero","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2025.102512_bib30","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1093\/bioinformatics\/btm030","article-title":"CGHcall: calling aberrations for array CGH tumor profiles","volume":"23","author":"van de Wiel","year":"2007","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2025.102512_bib31","doi-asserted-by":"crossref","first-page":"25715","DOI":"10.18632\/oncotarget.4706","article-title":"Reduced rate of copy number aberrations in mucinous colorectal carcinoma","volume":"6","author":"Hugen","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.xcrm.2025.102512_bib32","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/s40478-019-0873-5","article-title":"Investigation of somatic CNVs in brains of synucleinopathy cases using targeted SNCA analysis and single cell sequencing","volume":"7","author":"Perez-Rodriguez","year":"2019","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.xcrm.2025.102512_bib33","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13073-020-00735-4","article-title":"Shallow whole-genome sequencing of plasma cell-free DNA accurately differentiates small from non-small cell lung carcinoma","volume":"12","author":"Raman","year":"2020","journal-title":"Genome Med."},{"key":"10.1016\/j.xcrm.2025.102512_bib34","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/ijgc-2023-005073","article-title":"Evaluating the effectiveness of pre-operative diagnosis of ovarian cancer using minimally invasive liquid biopsies by combining serum human epididymis protein 4 and cell-free DNA in patients with an ovarian mass","volume":"34","author":"Gaillard","year":"2024","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.xcrm.2025.102512_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.labinv.2024.102091","article-title":"A Fast, Affordable, and Minimally Invasive Diagnostic Test for Cancer of Unknown Primary Using DNA Methylation Profiling","volume":"104","author":"De Wilde","year":"2024","journal-title":"Lab. Invest."},{"key":"10.1016\/j.xcrm.2025.102512_bib36","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2021.09.022","article-title":"The feasibility of using liquid biopsies as a complementary assay for copy number aberration profiling in routinely collected paediatric cancer patient samples","volume":"160","author":"Van Paemel","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.xcrm.2025.102512_bib37","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2025.102512_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.802579","article-title":"Immunotherapy in Breast Cancer and the Potential Role of Liquid Biopsy","volume":"12","author":"Magbanua","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.xcrm.2025.102512_bib39","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202216505","article-title":"Comparison of tumor-informed and tumor-na\u00efve sequencing assays for ctDNA detection in breast cancer","volume":"15","author":"Santonja","year":"2023","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.xcrm.2025.102512_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102914","article-title":"Landscape of circulating tumour DNA in metastatic breast cancer","volume":"58","author":"Davis","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.xcrm.2025.102512_bib41","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1186\/s12885-018-4637-6","article-title":"Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients","volume":"18","author":"McEvoy","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.xcrm.2025.102512_bib42","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1056\/NEJMoa1213261","article-title":"Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer","volume":"368","author":"Dawson","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2025.102512_bib43","doi-asserted-by":"crossref","first-page":"302ra133","DOI":"10.1126\/scitranslmed.aab0021","article-title":"Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer","volume":"7","author":"Garcia-Murillas","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2025.102512_bib44","doi-asserted-by":"crossref","first-page":"346ra92","DOI":"10.1126\/scitranslmed.aaf6219","article-title":"Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer","volume":"8","author":"Tie","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2025.102512_bib45","doi-asserted-by":"crossref","first-page":"pkaa122","DOI":"10.1093\/jncics\/pkaa122","article-title":"Applications of Circulating Tumor DNA in a Cohort of Phase I Solid Tumor Patients Treated With Immunotherapy","volume":"5","author":"Araujo","year":"2021","journal-title":"JNCI Cancer Spectr."},{"key":"10.1016\/j.xcrm.2025.102512_bib46","doi-asserted-by":"crossref","first-page":"4599","DOI":"10.1158\/1538-7445.AM2018-4599","article-title":"Abstract 4599: Detecting MSI phenotype in circulating blood DNA","volume":"78","author":"Stern","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102512_bib47","doi-asserted-by":"crossref","first-page":"4953","DOI":"10.1038\/s41467-022-32598-1","article-title":"Genome-wide mutational signatures in low-coverage whole genome sequencing of cell-free DNA","volume":"13","author":"Wan","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102512_bib48","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1002\/cncr.32876","article-title":"Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non\u2013small cell lung cancer: Analysis of over 8000 cases","volume":"126","author":"Mack","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.xcrm.2025.102512_bib49","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/ng.2760","article-title":"Pan-cancer patterns of somatic copy number alteration","volume":"45","author":"Zack","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.xcrm.2025.102512_bib50","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/nature08822","article-title":"The landscape of somatic copy-number alteration across human cancers","volume":"463","author":"Beroukhim","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.102512_bib51","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.102512_bib52","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nm.3886","article-title":"Subclonal diversification of primary breast cancer revealed by multiregion sequencing","volume":"21","author":"Yates","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2025.102512_bib53","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1038\/s41467-018-06052-0","article-title":"Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seq","volume":"9","author":"Karaayvaz","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102512_bib54","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1186\/1471-2407-8-362","article-title":"Tumor necrosis is associated with increased alphavbeta3integrin expression and poor prognosis in nodular cutaneous melanomas","volume":"8","author":"Bachmann","year":"2008","journal-title":"BMC Cancer"},{"key":"10.1016\/j.xcrm.2025.102512_bib55","doi-asserted-by":"crossref","first-page":"39676","DOI":"10.18632\/oncotarget.5344","article-title":"Tumor necrosis is an important hallmark of aggressive endometrial cancer and associates with hypoxia, angiogenesis and inflammation responses","volume":"6","author":"Bredholt","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.xcrm.2025.102512_bib56","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41392-023-01332-8","article-title":"Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions","volume":"8","author":"Chen","year":"2023","journal-title":"Sig. Transduct. Target Ther."},{"key":"10.1016\/j.xcrm.2025.102512_bib57","series-title":"Immune Homeostasis: Methods and Protocols","first-page":"65","article-title":"Detection of Necrosis by Release of Lactate Dehydrogenase Activity","author":"Chan","year":"2013"},{"key":"10.1016\/j.xcrm.2025.102512_bib58","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1731942","article-title":"Lactate dehydrogenase: a marker of diminished antitumor immunity","volume":"9","author":"Van Wilpe","year":"2020","journal-title":"OncoImmunology"},{"key":"10.1016\/j.xcrm.2025.102512_bib59","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1158\/1078-0432.CCR-17-0231","article-title":"Tumor Cell\u2013Free DNA Copy Number Instability Predicts Therapeutic Response to Immunotherapy","volume":"23","author":"Weiss","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102512_bib60","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aah3560","article-title":"Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance","volume":"9","author":"Roh","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2025.102512_bib61","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.3390\/cancers15133357","article-title":"Fluorometric Quantification of Total Cell-Free DNA as a Prognostic Biomarker in Non-Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Blockade","volume":"15","author":"Oliver","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.xcrm.2025.102512_bib62","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S1470-2045(22)00555-1","article-title":"Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial","volume":"23","author":"Bidard","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2025.102512_bib63","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2025.102512_bib64","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2025.102512_bib65","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1038\/s41467-024-46961-x","article-title":"Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study","volume":"15","author":"Lynce","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102512_bib66","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/s41586-020-2649-2","article-title":"Array programming with NumPy","volume":"585","author":"Harris","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.102512_bib67","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1109\/MCSE.2007.55","article-title":"Matplotlib: A 2D Graphics Environment","volume":"9","author":"Hunter","year":"2007","journal-title":"Comput. Sci. Eng."},{"key":"10.1016\/j.xcrm.2025.102512_bib68","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.21105\/joss.03021","article-title":"seaborn: statistical data visualization","volume":"6","author":"Waskom","year":"2021","journal-title":"JOSS"},{"key":"10.1016\/j.xcrm.2025.102512_bib69","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/s41592-019-0686-2","article-title":"SciPy 1.0: fundamental algorithms for scientific computing in Python","volume":"17","author":"Virtanen","year":"2020","journal-title":"Nat. Methods"},{"key":"10.1016\/j.xcrm.2025.102512_bib70","series-title":"Trevismd\/Statannotations: v0.6. Version v0.6.0","author":"Charlier","year":"2023"},{"key":"10.1016\/j.xcrm.2025.102512_bib29","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1101\/gr.175141.114","article-title":"DNA copy number analysis of fresh and formalin-fixed specimens by shallow whole-genome sequencing with identification and exclusion of problematic regions in the genome assembly","volume":"24","author":"Scheinin","year":"2014","journal-title":"Genome Res."},{"key":"10.1016\/j.xcrm.2025.102512_bib71","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1093\/bioinformatics\/btp132","article-title":"Smoothing waves in array CGH tumor profiles","volume":"25","author":"van de Wiel","year":"2009","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2025.102512_bib75","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1093\/bioinformatics\/bty1055","article-title":"ACE: absolute copy number estimation from low-coverage whole-genome sequencing data","volume":"35","author":"Poell","year":"2019","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2025.102512_bib72","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ccell.2022.11.014","article-title":"IL-5-producing CD4+ T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer","volume":"41","author":"Blomberg","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2025.102512_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.110425","article-title":"Predictive gene expression profile for adjuvant taxane benefit in breast cancer in the MATADOR trial","volume":"27","author":"Opdam","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.xcrm.2025.102512_bib74","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1158\/1078-0432.CCR-21-1442","article-title":"Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments","volume":"28","author":"Kester","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102512_bib77","doi-asserted-by":"crossref","first-page":"330","DOI":"10.5858\/arpa.2018-0043-OA","article-title":"Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer","volume":"143","author":"Kulangara","year":"2019","journal-title":"Arch. Pathol. Lab Med."},{"key":"10.1016\/j.xcrm.2025.102512_bib78","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/annonc\/mdy518","article-title":"Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study","volume":"30","author":"Adams","year":"2019","journal-title":"Ann. Oncol."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379125005853?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379125005853?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:54:53Z","timestamp":1790265293000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379125005853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":78,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2666379125005853"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.102512","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CfDNA-based copy-number dynamics during anti-PD1 treatment in metastatic triple negative breast cancer","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.102512","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102512"}}